Naftifine adverse reactions: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Naftifine}} {{CMG}}; {{AE}} {{AZ}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NAFTIN (NAFTIFINE HYDROCHLORIDE) CREAM [MERZ PHARM...")
 
No edit summary
 
(One intermediate revision by the same user not shown)
Line 3: Line 3:
{{CMG}}; {{AE}} {{AZ}}
{{CMG}}; {{AE}} {{AZ}}


==Adverse Reactions==


<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = NAFTIN (NAFTIFINE HYDROCHLORIDE) CREAM [MERZ PHARMACEUTICALS, LLC] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4b6c5d8-615c-47d6-8ad9-523c7ab146af | publisher =  | date =  | accessdate =  }}</ref>
During clinical trials with Naftin® Cream, 1%, the incidence of adverse reactions was as follows: burning/stinging (6%), dryness (3%), erythema (2%), itching (2%), local irritation (2%). During clinical trials with Naftin® Gel, 1%. the incidence of adverse reactions was as follows: burning Istinging (5.0%), [[itching]] (1.0%), [[erythema]] (0.5%), [[rash]] (0.5%), skin tenderness (0.5%).<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = NAFTIN (NAFTIFINE HYDROCHLORIDE) CREAM [MERZ PHARMACEUTICALS, LLC] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f4b6c5d8-615c-47d6-8ad9-523c7ab146af | publisher =  | date =  | accessdate =  }}</ref>
 
==References==
==References==
{{Reflist}}
{{Reflist}}

Latest revision as of 03:39, 9 January 2014

Naftifine
Naftin® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Adverse Reactions

During clinical trials with Naftin® Cream, 1%, the incidence of adverse reactions was as follows: burning/stinging (6%), dryness (3%), erythema (2%), itching (2%), local irritation (2%). During clinical trials with Naftin® Gel, 1%. the incidence of adverse reactions was as follows: burning Istinging (5.0%), itching (1.0%), erythema (0.5%), rash (0.5%), skin tenderness (0.5%).[1]

References

  1. "NAFTIN (NAFTIFINE HYDROCHLORIDE) CREAM [MERZ PHARMACEUTICALS, LLC]".

Adapted from the FDA Package Insert.